10 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 10, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Severe Dengue: new trials by email Literature Review of Severe Dengue trials Research Report on Severe Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients Montelukast, Placebo - Dengue, Dengue With Warning Signs | Phase 2 / Phase 3 | Completed | Phramongkutklao College of Medicine and Hospital | 358 | 2021-01-15 | 2023-07-18 |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed, Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 688 | 2016-12-19 | 2022-03-25 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 528 | 2016-12-01 | 2022-03-25 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 480 | 2016-11-16 | 2022-03-25 |
| Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine - Dengue, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 792 | 2011-09-07 | 2022-03-25 |
| Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus, DTaP IPV//Hib vaccine, Placebo - Dengue, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 720 | 2011-07-18 | 2022-03-25 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Live, attenuated, dengue serotype 1, 2, 3, 4 virus, Placebo: (NaCl) 0.9% solution - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 20869 | 2011-06-08 | 2022-03-21 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Live, attenuated, dengue serotype 1, 2, 3, 4 virus, Placebo: Sodium chloride (NaCl) 0.9% - Dengue, Dengue Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 10275 | 2011-06-03 | 2022-03-21 |
| Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Placebo: NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi | 250 | 2010-12-02 | 2022-03-25 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus, Placebo: NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 715 | 2010-10-05 | 2019-07-24 |
| Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Hypertonic sodium lactate, Ringer's lactate - Dengue Shock Syndrome | Phase 3 | Unknown | Innogene Kalbiotech Pte. Ltd | 50 | 2008-05-01 | 2009-08-28 |
Dengue (13) · Flavivirus Infections (2) · Arbovirus Infections (1) · Hemorrhage (1) · Hemorrhagic Fevers, Viral (1) · Mosquito-Borne Diseases (1) · RNA Virus Infections (1) · Vector Borne Diseases (1) · Yellow Fever (1)
Flaviviridae Infections (13) · Infections (13) · Virus Diseases (13) · Arbovirus Infections (12) · Hemorrhagic Fevers, Viral (12) · Mosquito-Borne Diseases (12) · RNA Virus Infections (12) · Vector Borne Diseases (12) · Flavivirus Infections (11) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Dengue Vaccines (3) · Measles-Mumps-Rubella Vaccine (2) · Sodium Chloride (2) · Acetylcysteine (1) · Dexamethasone (1) · Haemophilus Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Pentavac (1) · Pneumococcal Vaccines (1) · Ribavirin (1) · Ringer's Lactate (1) · Solutions (1) · Standard of Care (1) · Tetanus Toxoid (1)
Sanofi Pasteur, a Sanofi Company (8) · Innogene Kalbiotech Pte. Ltd (1) · Khyber Medical University Peshawar (1) · Oxford University Clinical Research Unit, Vietnam (1) · Phramongkutklao College of Medicine and Hospital (1) · Sanofi (1)
Malaysia (4) · Colombia (3) · Indonesia (3) · Mexico (3) · Philippines (3) · Thailand (3) · Brazil (2) · Peru (2) · Vietnam (2) · Australia (1) · Bangladesh (1) · Honduras (1) · Nepal (1) · Pakistan (1) · Puerto Rico (1)
Akhtar Sherin, MBBS,MHR,PHD (1) · Dadang H Somasetia, SpA(K), MKes (1) · Noman Arif, MBBS (1) · Said Amin, MBBS,FCPS (1) · Sheraz Fazid, MBBS,MPH (1) · Sophie Yacoub, MD., PhD. (1) · Worapong Nasomsong, MD (1) · Worayon Chuerboonchai, MD (1) · Xavier Leverve, MD, PhD (1)
PMID 26214039, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 29897841, PMID 33212068, PMID 33822015, PMID 34003796, PMID 34219653, PMID 35659904, PMID 24135573, PMID 25018116, PMID 25189175, PMID 25365753, PMID 26279339, PMID 26614588, PMID 26639777, PMID 27414655, PMID 27532617, PMID 27601343, PMID 28590795, PMID 28598256, PMID 28968794, PMID 29408333, PMID 32040014, PMID 33992441, PMID 34117198, PMID 34250977, PMID 38306389
2019 (3), 2014 (2)